Document is current
Any future updates will be listed below
-
Authors
Shteinman, Eva R.
Attrill, Grace H.
Maher, Nigel G.
Gnana, Kiran
Addala, Venkateswar
Mao, Yizhe
Palendira, Umaimainthan
Conway, Jordan W.
Colebatch, Andrew J.
Waddell, Nicola
Hayward, Nicholas K.
Pearson, John V.
Long, Georgina V.
Scolyer, Richard A.
Wilmott, James S.
Vergara, Ismael A.
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council of Australia (NHMRC) Investigator Grant (2022/GNT2018514)
National Health and Medical Research Council of Australia (NHMRC) Investigator Fellowship (APP1174325)
- License Information
-
More Information
Article History
Received: 22 May 2025
Accepted: 19 May 2026
First Online: 26 May 2026
Declarations
:
: The experiment proceeded in accordance with the National Health and Medical Research Council of Australia’s National Statement on Ethical Conduct in Human Research. All patients gave written informed consent, and the study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Human Research Ethics Committee of Sydney Local Health District RPA Zone Human Research Ethics Committee (protocol no. X15-0454 and HREC/11/RPAH/444).
: Not applicable.
: N.W., and J.V.P. are co-founders of genomiQa. G.V.L. is consultant advisor for Agenus, Amgen, Array Biopharma, AstraZeneca, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Evaxion, Hexal AG (Sandoz Company), Highlight Therapeutics S.L., Immunocore, Innovent Biologics USA, Merck Sharpe & Dohme, Novartis, PHMR Ltd, Pierre Fabre, Provectus, Qbiotics, Regeneron. R.A.S. has received fees for professional services from SkylineDx BV, IO Biotech ApS, MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline. The other authors declare no competing interests.
